Know Cancer

forgot password

A Phase I/II Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer

Phase 1/Phase 2
18 Years
Not Enrolling
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Phase I/II Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer

ZD6474 is a new drug that is thought to block the formation of new blood vessels. The growth
of new blood vessels is called angiogenesis. Angiogenesis is thought to be essential for
the growth of tumors beyond a small size.

Before treatment starts, you will have several tests and procedures performed. These tests
will include a complete medical history and physical exam, including recent weight loss,
vital signs, and a test to check how easily you swallow. Laboratory tests needed will
require a urine sample, and blood samples (about 3-4 teaspoons). Women who are able to have
children must have a negative blood pregnancy test in order to participate in this study.
You will have an electrocardiogram (ECG--a test to measure the electrical activity of the
heart), heart function tests, and scans of your brain, chest, and bones. You will also have
PET scans performed.

You may take part in this study if you are a patient with NSCLC who is not able to receive

If you are eligible to participate, you will receive ZD6474 by mouth once a day every day,
along with radiation therapy. You must take your medication on an empty stomach, at
approximately the same time each morning. ZD6474 should be swallowed as a whole tablet (not
chewed, crushed or divided) and taken with 8 oz of water. Missed doses may be taken by the
end of the same calendar day. However, if a subject misses taking their scheduled dose on
the same day, he or she must take the next scheduled dose and the missed dose will not be
made up. The missed dose must be documented on patients medication diary ZD6474 will be
given 5-7 days before starting radiation therapy and will continue through the entire course
of radiation therapy, unless there is proof that the cancer is progressing. ZD6474 may
interact with many commonly prescribed medications. A list will be provided to you.

Radiation will be given every weekday (Monday - Friday) for 3-7 weeks as your doctor thinks
is necessary and useful. You will have weekly evaluations during radiation treatment,
including blood samples (3-4 teaspoons) for routine testing, oxygen saturation (a test that
measures how much oxygen is in the blood), and physical examination.

If you need anti-nausea medication (such as Zofran) during this study, you will have an ECG
performed within 24 hours of starting the medication and then again at least once a week
while you remain on the medication.

You will continue on study, unless there is evidence that the disease has gotten worse or
intolerable side effects occur.

You will be seen for a follow-up visit one month after completing radiation therapy, and
again at 3 months. You will then come in for a follow-up visit every 3 months for 2 years,
then every 6 months for 3 years, then once a year. Scheduled tests and follow-ups should
be performed within 1 week (before or after) of the scheduled time period (a 14-day window).
At these visits, you will have blood draws (about 3-4 teaspoons), urine tests and x-rays.
You will have an ECG, lung function tests, and PET/CT scans.

Participants who are blood donors should not donate blood during the study and for 3 months
following their last dose of study treatment.

This is an investigational study. ZD6474 is not FDA approved, and has been authorized for
research only. A total of up to 48 patients will take part in this study. All patients
will be enrolled at UTMDACC.

Inclusion Criteria:

1. Non-small cell lung cancer patients Stage I-IV with surgically unresectable or
medically inoperable tumors.

2. Patients for whom radiation therapy alone is the recommended treatment, who are not
candidates for other chemo-radiation protocols.

3. For Phase I: Patients with any stage for whom palliative radiation therapy to 45
Gy/15 Fx is the recommended treatment (patients with obstructive pneumonia are

4. The primary tumor and/or regional lymphatic metastases must be evaluable

5. Have at least one lesion greater than 2 cm in diameter measurable by CT.

6. Age at least 18 years old.

7. Karnofsky performance status >/=50, weight loss < 30% within the previous 6 months.

8. No prior invasive malignancies less than or equal to 3 years prior to study entry and
no prior radiation to the thorax.

9. ALT or AST < 2.5 ULN or alk phos (ALP) < 2.5 x ULN, or < 5x ULN if judged by the
investigator to be related to liver metastases

10. Total bilirubin < 1.5 x ULN or <3 x ULN if related to liver metastases

11. Serum creatinine < 1.5 x ULRR or creatinine clearance greater than or equal to 50
mL/minute (calculated by Cockcroft-Gault formula.)

12. WBC > 3000/mm3, serum hemoglobin >/= 8 gm/dl, platelet count >/= 100,000/mm3,
absolute granulocyte count >/= 2,000.

13. INR within normal laboratory value range and PT and PTT within 3 seconds of normal

14. Potassium must be within normal laboratory value range. Serum calcium and magnesium
must be within normal range. Supplementation may be used to normalize.

15. Patients with distant metastases and life expectancy greater than or equal to 3
months are eligible.

16. Due to the experimental nature of ZD6474, female patients must be one year
post-menopausal, surgically sterile, or using an acceptable method of contraception
(oral contraceptives, barrier methods, approved contraceptive implant, long-term
injectable contraception, intrauterine device or tubal ligation.) Male patients must
be surgically sterile or using an acceptable method of contraception during their
participation in this study.

17. A negative pregnancy test within 72 hours prior to administration of ZD6474 will be
required for women of childbearing potential.

18. Patients must sign an informed consent indicating that they are aware of the
investigational nature of the study in keeping with the policy of M.D. Anderson
Cancer Center. Patients must also agree to study restrictions and return for required
assessments. The only approved consent form is attached to this protocol.

19. Eligibility for Phase II: (A) Patients with medically inoperable stage I and II NSCLC
for whom definitive XRT alone is recommended (not candidate for combined chemo-XRT),
or, (B) Patients who received previous induction chemotherapy off protocol, not
candidates for other chemo-XRT protocols, or, (C) Patients with stage III NSCLC for
whom definitive XRT alone is recommended, or, (D) Patients with any stage for whom
palliative radiation therapy to 45 Gy/15 Fx is recommended.

20. Patients who are blood donors should not donate blood during the trial and for 3
months following their last dose of trial treatment.

Exclusion Criteria:

1. Pregnancy or breast feeding

2. Bronchoalveolar carcinoma

3. Oxygen saturation less than 90% on room air or requirement for oxygen supplementation

4. Any condition that is likely to interfere with regular follow-up

5. Patient cannot have participated in any clinical trial involving conventional or
investigational drugs within 4 weeks prior to administration of ZD6474

6. Patient cannot have received radiation therapy or chemotherapy within 4 weeks prior
to administration of ZD6474 (6 weeks for nitrosoureas and mitomycin)

7. Patient cannot be receiving herbal remedies or other over-the-counter biologics
(e.g., shark cartilage)

8. Patient cannot be receiving drugs with known significant 3A4 inhibitory effects
(e.g., ketoconazole, erythromycin, and verapamil - See Appendix K)

9. Patient cannot be receiving drugs with known corneal toxicology (e.g., tamoxifen,
chlorpromazine, amiodarone, and chloroquine)

10. Patients cannot have received previous treatment with agents that block the EGF or
VEGF pathways

11. Patient cannot have serum calcium levels below the lower limits of normal.

12. Clinically significant cardiac event such as myocardial infarction; New York Heart
Association (NYHA) classification of heart disease >/=2 (see Appendix J) within 3
months before entry; or presence of cardiac disease that, in the opinion of the
Investigator, increases the risk of ventricular arrhythmia.

13. History of arrhythmia (multifocal premature ventricular contractions (PVCs),
bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation)
which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained
ventricular tachycardia. Atrial fibrillation, controlled on medication is not

14. QTc with Bazett's correction that is unmeasurable, or >/= 480 msec on screening ECG.
If a patient has QTc >/= 480 msec on screening EKG, the screening EKG may be repeated
twice (at least 24 hours apart). The average QTc from the three screening EKGs must
be <480 msec in order for the patient to be eligible for the study.

15. Patients cannot have a history of QT prolongation with other medication

16. Patients cannot have a congenital long QT syndrome or 1st degree relative with
unexplained sudden death under 40 years of age.

17. Any concomitant medications that affect QTc or induce Torsades de Pointes (Appendix
E) and cannot be discontinued

18. Left ventricular ejection fraction less than 45% measured by multigated blood-pool
imaging (MUGA) or Echocardiogram for subjects with previous anthracycline therapy
(total dose greater than 450 mg/m2) or significant cardiovascular disease

19. Patients cannot have a severe hypersensitivity reaction to drugs formulated with
polysorbate 80

20. Patients cannot have any evidence of severe or uncontrolled systemic disease,
including known Hepatitis B or HIV infection. Screening for chronic conditions is not
required, although subjects known to have such conditions should not be enrolled.

21. Patient cannot have had any active cancer in addition to their current lung cancer
within the last 3 years with the exception of superficial skin cancer (e.g., basal
cell or squamous cell carcinoma)

22. Patient cannot have any CNS metastases, unless treated at least 4 weeks before entry,
and stable without steroid treatment for 1 week

23. Patient cannot have any additional uncontrolled serious medical or psychiatric

24. Patients with other contraindication for radiation therapy as decided by the

25. Patients cannot have presence of a left bundle branch block (LBBB).

26. Hypertension not controlled by medical therapy (systolic blood pressure > 140 mm Hg
or diastolic blood pressure > 90 mm Hg)

27. Major surgery within 4 weeks, or incompletely healed surgical incision before
starting study therapy

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose (MTD)

Outcome Time Frame:

Weekly evaulations from baseline through 3 to 7 weeks of treatment (3-5 days per week for radiation and up to 3 doses tested)

Safety Issue:


Principal Investigator

Melenda D. Jeter, MD, MPH

Investigator Role:

Principal Investigator

Investigator Affiliation:

Assistant Professor, UT MDACC


United States: Food and Drug Administration

Study ID:




Start Date:

October 2008

Completion Date:

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • Lung Cancer
  • ZD6474
  • Vandetanib
  • Inoperable NSCLC
  • Unresectable NSCLC
  • Radiation Therapy
  • Palliative radiation therapy
  • Angiogenesis
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



UT MD Anderson Cancer CenterHouston, Texas  77030